Business
Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting
New data highlighting the potential of human islet cell transplantation for type 1 diabetes will be presented SEATTLE, June 13, 2022 (GLOBE NEWSWIRE) -- Sana
About this update from Sana Biotechnology, Inc.
[{"type":"text","content":"New data highlighting the potential of human islet cell transplantation for type 1 diabetes will be presented\nSEATTLE, June 13, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company will present data from its hypoimmune platform at the International Society for Stem Cell Research (ISSCR) 2022 Annual Meeting taking place from Wednesday, June 15 through Sunday, June 19 in San Francisco. Oral Presentation: Title:Protecting islets from immune destruction with hypoimmune iPSCsSession:Stem cell COREdinates tools for basic and applied stem cell biologyDate/Time:Wednesday, June 15 from 10:50 a.m. – 11:10 a.m. PT Poster Presentations: Title:Overcoming the immune barrier is key to unlocking the potential of human islet transplantation for type 1 diabetesPoster No:212Date/Time:Wednesday, June 15 from 7:30 p.m. – 8:30 p.m. PT Title:Allogeneic iPSCs survive without immunosuppression in a translational non-human primate (NHP) modelPoster No:220Date/Time:Thursday, June 16 from 4:00 p.m. – 5:00 p.m. PT Workshop Presentation: Title:Unleashing cells from immune rejection to make off-the-shelf therapiesWorkshop:How to Make Clinically Successful Cell Therapies, Session IIIDate/Time:Tuesday, June 14 from 3:20 p.m. – 3:50 p.m. PT About Sana BiotechnologySana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the company’s vision, progress, and business plans, the Company’s participation at the ISSCR Annual Meeting, and the subject matter of the Company’s presentations and data being presented at ISSCR Annual Meeting. All statements other than statements of historical facts contained in t...